https://endpts.com/sp/biotech-halftime-report-after-a-bumpy-year-is-biotech-ready-to-rebound/
Biopharma firms are flush with cash and with looming patent cliffs and depressed valuations among some smaller firms, we could see more deal activity through year-end. The possibility is further bolstered by management commentary, which continues to suggest openness to M&A deals. What’s changed is that large biopharma seems to be preferring smaller, earlier stage deals, private companies, or discounted late-stage assets, rather than the large $15 billion acquisitions we’ve seen in the past.
Where others have failed will Atl1102 succeed ?, page-910
-
- There are more pages in this discussion • 187 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
